<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The role of the nucleophosmin (NPM1) mutations in de novo <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) is well analyzed, but the impact in <z:e sem="disease" ids="C0280449" disease_type="Neoplastic Process" abbrv="">secondary AML</z:e> (s-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) following <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) or transformed myeloproliferative <z:hpo ids='HP_0002664'>neoplasms</z:hpo> (MPNs) remains unclear </plain></SENT>
<SENT sid="1" pm="."><plain>We investigated 350 patients-283 s-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> after <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and 67 transformed MPNs-for NPM1mut </plain></SENT>
<SENT sid="2" pm="."><plain>NPM1mut was detected in 43/350 patients (12.3%) at diagnosis of s-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (transformed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>: 37/283; 13.1%; transformed MPNs: 6/67; 9.0%) </plain></SENT>
<SENT sid="3" pm="."><plain>Cytogenetic alterations were present in 12/40 cases (30.0%) with available karyotypes </plain></SENT>
<SENT sid="4" pm="."><plain>Additional molecular mutations were found in 23/43 NPM1mut s-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> after <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (53.5%) and in transformed MPN in 18/37 (48.6%): FLT3-ITD: 14/37 (37.8%); FLT3-TKD: 3/28 (10.7%); NRASmut: 4/37 (10.8%), RUNX1mut: 1/16 (6.3%) </plain></SENT>
<SENT sid="5" pm="."><plain>In NPM1mut-transformed MPNs, five out of six cases showed 1-2 additional molecular mutations (2 × KITD816V, ETV6-PDGFRB, 2 × JAK2V617F, 2 × FLT3-ITD) </plain></SENT>
<SENT sid="6" pm="."><plain>Backtracking of nine of these cases by quantitative real time PCR showed the NPM1mut already at diagnosis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/MPN, at variable levels and up to 14 months before diagnosis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, and at transformation often being preceded or accompanied by other genetic alterations </plain></SENT>
<SENT sid="7" pm="."><plain>Thus, NPM1 mutations are involved in the transformation from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> or MPN to <z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blast phase</z:e> in single cases, which should be further confirmed in larger studies </plain></SENT>
</text></document>